Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD

David R. Coghill; Alain Joseph; Vanja Sikirica; Mark Kosinski; Caleb Bliss; Michael Huss

doi:10.1177/1087054717723984

Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD

David R. Coghill (Lead / Corresponding author), Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huss

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

282 Downloads (Pure)

Abstract

Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD.

Method: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference).

Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance ( r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort ( r ≈ .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score ( r ≈ .5). CHIP-CE: PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score ( r ≈ .6).

Conclusion: The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.

Original language	English
Pages (from-to)	1578-1591
Number of pages	14
Journal	Journal of Attention Disorders
Volume	23
Issue number	13
Early online date	24 Aug 2017
DOIs	https://doi.org/10.1177/1087054717723984
Publication status	Published - 2018

Keywords

ADHD
CHIP-CE
HRQoL
Functional impairment
Pharmacological treatment

Access to Document

10.1177/1087054717723984Licence: CC BY-NC

Final Published VersionFinal published version, 458 KBLicence: CC BY-NC

Cite this

@article{5d0e28e2728a432aaefa2a25822deffb,

title = "Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD",

abstract = "Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD.Method: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference).Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance ( r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort ( r ≈ .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score ( r ≈ .5). CHIP-CE: PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score ( r ≈ .6).Conclusion: The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.",

keywords = "ADHD, CHIP-CE, HRQoL , Functional impairment , Pharmacological treatment",

author = "Coghill, {David R.} and Alain Joseph and Vanja Sikirica and Mark Kosinski and Caleb Bliss and Michael Huss",

note = "The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This post hoc analysis and the two original studies were funded by the sponsor, Shire Development LLC.",

year = "2018",

doi = "10.1177/1087054717723984",

language = "English",

volume = "23",

pages = "1578--1591",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications",

number = "13",

}

Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. / Coghill, David R. (Lead / Corresponding author); Joseph, Alain; Sikirica, Vanja et al.
In: Journal of Attention Disorders, Vol. 23, No. 13, 2018, p. 1578-1591.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD

AU - Coghill, David R.

AU - Joseph, Alain

AU - Sikirica, Vanja

AU - Kosinski, Mark

AU - Bliss, Caleb

AU - Huss, Michael

N1 - The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This post hoc analysis and the two original studies were funded by the sponsor, Shire Development LLC.

PY - 2018

Y1 - 2018

N2 - Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD.Method: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference).Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance ( r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort ( r ≈ .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score ( r ≈ .5). CHIP-CE: PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score ( r ≈ .6).Conclusion: The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.

AB - Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD.Method: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference).Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance ( r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort ( r ≈ .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score ( r ≈ .5). CHIP-CE: PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score ( r ≈ .6).Conclusion: The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.

KW - ADHD

KW - CHIP-CE

KW - HRQoL

KW - Functional impairment

KW - Pharmacological treatment

U2 - 10.1177/1087054717723984

DO - 10.1177/1087054717723984

M3 - Article

C2 - 28836895

SN - 1087-0547

VL - 23

SP - 1578

EP - 1591

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 13

ER -

Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD

Abstract

Keywords

Access to Document

Fingerprint

Cite this